Skip to main content
SpringerLink
Log in

Cyclooxygenase-2 and intestinal cancer

  • Chapter
New Targets in Inflammation

Abstract

Multiple epidemiological studies reveal a 40–50% reduction in mortality from colorectal cancer in individuals taking non-steroid anti-inflammatory drugs (NSAIDs) on a regular basis compared with those not taking these agents1–6. Persons with familial adenomatous polyposis (FAP) who take sulindac show a striking reduction in adenoma size and number7–11. In rodent models of azoxymethane-induced colorectal carcinogenesis, cyclooxygenase (COX) inhibitors exhibit chemoprotective effects as judged by a reduction in the frequency and number of premalignant and malignant lesions12–24 Recently, Jacoby et al.15 reported a decrease in tumour number in Min (multiple intestinal neoplasia) mice treated with piroxicam.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Giovannucci E, Egan KM, Hunter DJ et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med. 1995;333:609–14.

    Article  PubMed  CAS  Google Scholar 

  2. Greenberg ER, Baron JA, Freeman DHJ, Mandel JS, Haile R. Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group. J Natl Cancer Inst. 1993;85: 912–16.

    Article  PubMed  CAS  Google Scholar 

  3. Thun MJ, Namboodiri MM, Heath CWJ. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 1991;325:1593–6.

    Article  CAS  Google Scholar 

  4. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CWJ. Aspirin use and risk of fatal cancer. Cancer Res. 1993;53:1322–7.

    PubMed  CAS  Google Scholar 

  5. Peleg II, Maibach HT, Brown SH, Wilcox CM. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med. 1994;154:394–9.

    Article  PubMed  CAS  Google Scholar 

  6. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med. 1994; 121:241–6.

    PubMed  CAS  Google Scholar 

  7. Giardiello FM, Hamilton SR, Krush AJ et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 1993;328:1313–16.

    Article  PubMed  CAS  Google Scholar 

  8. Waddell WR, Loughry RW. Sulindac for polyposis of the colon. J Surg Oncol. 1983;24:83–7.

    Article  PubMed  CAS  Google Scholar 

  9. Waddell WR, Gasner GF, Cerise EJ, Loughry RW. Sulindac for polyposis of the colon. Am J Surg. 1989;157:175–8.

    Article  PubMed  CAS  Google Scholar 

  10. Winde G, Gumbinger HG, Osswald H, Kemper F, Bunte H. The NSAID sulindac reverses rectal adenomas in colectomized patients with familial adenomatous polyposis: clinical results of a dose-finding study on rectal sulindac administration. Int J Colorectal Dis. 1993;8:13–17.

    Article  PubMed  CAS  Google Scholar 

  11. Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg. 1993;80:1618–19.

    Article  PubMed  CAS  Google Scholar 

  12. Reddy BS, Nayini J, Tokumo K, Rigotty J, Zang E, Kelloff G. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,L-alpha-difluoromethylornithine, an omithine decarboxylase inhibitor, in diet. Cancer Res. 1990;50:2562–8.

    PubMed  CAS  Google Scholar 

  13. Reddy BS, Rao CV, Rivenson A, Kelloff G. Inhibitor effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis. 1993;14:1493–7.

    Article  PubMed  CAS  Google Scholar 

  14. Craven PA, DeRubertis FR. Effects of aspirin on 1,2-dimethylhydrazine-induced colonic carcinogenesis. Carcinogenesis. 1992;13:541–6.

    Article  PubMed  CAS  Google Scholar 

  15. Jacoby RF, Marshall DJ, Newton MA et al. Chemoprevention of spontaneous intestinal adenomas in the АрcMinmouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res. 1996;56:710–14.

    PubMed  CAS  Google Scholar 

  16. Eberhart CE, DuBois RN. Eicosanoids and the gastrointestinal tract. Gastroenterology. 1995;109: 285–301.

    Google Scholar 

  17. Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med. 1993;122:5l8–23.

    Google Scholar 

  18. Rao CV, Rivenson A, Simi B et al. Chemoprevention of colon carcinogenesis by sulindac, a non-steroidal anti-inflammatory agent. Cancer Res. 1995;55:1464–72.

    PubMed  CAS  Google Scholar 

  19. Shiff SJ, Qiao L., Tsai LL, Rigas B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest. 1995;96:491–503.

    Article  PubMed  CAS  Google Scholar 

  20. Lu X, Xie W, Reed D, Bradshaw WS, Simmons DL. Nonsteroidal antiinflammatory drugs cause apoptosis and induce cyclooxygenase in chicken embryo fibroblasts. Proc Nat’ Acad Sci USA. 1995;92:7961–5.

    Article  CAS  Google Scholar 

  21. Piazza GA, Rahm AL, Krutzsch M et al. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res. 1995;55:3110–16.

    PubMed  CAS  Google Scholar 

  22. Williams CW, DuBois RN. Prostaglandin endoperoxide synthase: why two isoforms? Am J Physiol. 1996;270:G393–G400.

    PubMed  CAS  Google Scholar 

  23. DuBois RN, Awad J, Morrow J, Roberts LJ, Bishop PR. Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-a and phorbol ester. J Clin Invest. 1994;93:493–8.

    Article  PubMed  CAS  Google Scholar 

  24. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells over-expressing prostaglandin endoperoxide synthase-2. Cell. 1995;83:493–501.

    Article  PubMed  CAS  Google Scholar 

  25. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Bio] Chem. 1993;268:6610–14.

    CAS  Google Scholar 

  26. Masferrer JL, Zweifel BS, Manning PT et al. Selective inhibition of inducible cyclooxygenase-2 in vivo is antiinflammatory and nonulcerogenic. Proc Nati Acad Sci USA. 1994;91:3228–32.

    Article  CAS  Google Scholar 

  27. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994;107:1183–8.

    PubMed  CAS  Google Scholar 

  28. Kargman S, O’Neill G, Vickers P, Evans J, Mancini J, Jothy S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res. 1995;55:2556–9.

    PubMed  CAS  Google Scholar 

  29. Sano H, Kawahito Y, Wilder RL et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 1995;55:3785–9.

    PubMed  CAS  Google Scholar 

  30. Liu T, Mikuolu AO, Rao CV, Reddy BS, Holt PR. Regional chemoprevention of carcinogen-induced tumors in rat colon. Gastroenterology. 1995;109:1167–72.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. R. N. Dubois
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Radhika
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Shao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Tsujii
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. Sheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. O. Kobyashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R. D. Beauchamp
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C. S. Williams
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. LSU Neuroscience Center, Louisiana State University Medical Center, School of Medicine, New Orleans, LA, 70112, USA

    Nicolas Bazan

  2. The William Harvey Research Institute, St Bartholomew’s Hospital Medical College, Charterhouse Square, London, EC1M 6BQ, UK

    Jack Botting  & John Vane  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Dubois, R.N. et al. (1996). Cyclooxygenase-2 and intestinal cancer. In: Bazan, N., Botting, J., Vane, J. (eds) New Targets in Inflammation. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-5386-7_14

Download citation

  • DOI: https://doi.org/10.1007/978-94-011-5386-7_14

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-6265-7

  • Online ISBN: 978-94-011-5386-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation